articleThe Lancet Diabetes & EndocrinologyMay 22, 2017GREEN OA

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

HGHenry G. BoneRBRachel B. WagmanMLMaria Luisa BrandiJPJacques P. BrownRCRoland Chapurlat

University of Michigan · Amgen (United States) · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

954
total citations
FWCI
69.86
Percentile
100%
References
37
Citations per year

Authors

20

Topics & keywords

Topics
Keywords
  • Denosumab
  • Medicine
  • Placebo
  • Osteoporosis
  • Adverse effect
  • Incidence (geometry)
  • Femoral neck
  • Randomized controlled trial
UN Sustainable Development Goals
  • Gender equality
No related works found for this paper.